Literature DB >> 7125409

Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia.

J C Wade, S C Schimpff, K A Newman, P H Wiernik.   

Abstract

Staphylococcus epidermidis, a major component of the skin flora, is usually considered a contaminant when recovered from diagnostic cultures. Since 1974 infections caused by gram-negative bacilli and S. aureus occurring among patients with granulocytopenic cancer have remained constant; infections due to S. epidermidis occurring before 1977 at a rate of 2.0 per 1000 days of hospitalization of patients with acute leukemia, increased to 14.6 per 1000 days in 1979. All S. epidermidis infections before 1977 originated from skin sites; since 1977 the respiratory tract and alimentary canal have become the predominant sites of origin. Predisposing factors for infection were profound granulocytopenia (less than 100/microL), a diagnosis of acute leukemia, and an oral nonabsorbable antibiotic regimen lacking vancomycin. The increased incidence of infection was not related to a nosocomial source or the more frequent use of long-term indwelling catheters. Methicillin resistance among isolates was common (40%). Intravenous vancomycin therapy provided the best therapeutic results. Diagnostic cultures positive for S. epidermidis in the setting of infection and profound granulocytopenia warrant appropriate antibiotic therapy.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7125409     DOI: 10.7326/0003-4819-97-4-503

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  93 in total

1.  Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients.

Authors:  D Yamamura; R Gucalp; P Carlisle; M Cimino; J Roberts; C Rotstein
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 2.  Understanding the significance of Staphylococcus epidermidis bacteremia in babies and children.

Authors:  Gordon Y C Cheung; Michael Otto
Journal:  Curr Opin Infect Dis       Date:  2010-06       Impact factor: 4.915

3.  Impact of blood cultures drawn by phlebotomy on contamination rates and health care costs in a hospital emergency department.

Authors:  Rita M Gander; Linda Byrd; Michael DeCrescenzo; Shaina Hirany; Michelle Bowen; Judy Baughman
Journal:  J Clin Microbiol       Date:  2009-01-26       Impact factor: 5.948

4.  Bactericidal activity of oxacillin against beta-lactamase-hyperproducing Staphylococcus aureus.

Authors:  G L Woods; P Yam
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

5.  [Septicemia in leukemia and malignant lymphoma. Incidence pathogens--causes].

Authors:  H H Hennemann
Journal:  Klin Wochenschr       Date:  1985-09-02

6.  Bactericidal activity of ceftazidime in serum compared with that of ticarcillin combined with amikacin.

Authors:  H C Standiford; G L Drusano; B Fitzpatrick; B Tatem; S C Schimpff
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

7.  Frequent detection of multidrug-resistant pneumonia-causing bacteria in the pneumonia lung tissues of patients with hematological malignancies.

Authors:  Kunihiro Inai; Hiromichi Iwasaki; Sakon Noriki; Satoshi Ikegaya; Masanori Yamashita; Yoshiaki Imamura; Nobuo Takimoto; Hisataka Kato; Takanori Ueda; Hironobu Naikia
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

8.  Immunochemical analysis of the extracellular slime substance of Staphylococcus epidermidis.

Authors:  P Kotilainen; J Mäki; P Oksman; M K Viljanen; J Nikoskelainen; P Huovinen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-04       Impact factor: 3.267

9.  Role of the Staphylococcus epidermidis slime layer in experimental tunnel tract infections.

Authors:  C C Patrick; M R Plaunt; S V Hetherington; S M May
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

10.  In vitro susceptibilities of four species of coagulase-negative staphylococci.

Authors:  R J Fass; V L Helsel; J Barnishan; L W Ayers
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.